(0.25%) 5 112.82 points
(0.23%) 38 327 points
(0.24%) 15 967 points
(-1.45%) $82.63
(3.80%) $1.996
(0.06%) $2 348.60
(-0.35%) $27.44
(3.68%) $956.05
(-0.17%) $0.933
(-0.25%) $11.00
(-0.46%) $0.797
(1.74%) $93.47
Live Chart Being Loaded With Signals
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally...
Stats | |
---|---|
本日の出来高 | 1.26M |
平均出来高 | 11.66M |
時価総額 | 417.88M |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -0.360 |
ATR14 | HKD0.00500 (0.52%) |
ボリューム 相関
Kintor Pharmaceutical Ltd 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Kintor Pharmaceutical Ltd 相関 - 通貨/商品
Kintor Pharmaceutical Ltd 財務諸表
Annual | 2022 |
収益: | HKD0 |
総利益: | HKD0 (0.00 %) |
EPS: | HKD-2.53 |
FY | 2022 |
収益: | HKD0 |
総利益: | HKD0 (0.00 %) |
EPS: | HKD-2.53 |
FY | 2021 |
収益: | HKD34.23M |
総利益: | HKD34.23M (100.00 %) |
EPS: | HKD-2.72 |
FY | 2020 |
収益: | HKD0.00 |
総利益: | HKD0.00 (0.00 %) |
EPS: | HKD-1.640 |
Financial Reports:
No articles found.
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。